Role of Physical Therapists in the Management of Individuals at Risk for or Diagnosed With Venous Thromboembolism: Evidence-Based Clinical Practice Guideline [PDF]
, 2016 The American Physical Therapy Association (APTA), in conjunction with the Cardiovascular & Pulmonary and Acute Care sections of APTA, have developed this clinical practice guideline to assist physical therapists in their decision-making process when ...
Auten, Beth +5 more
core +1 more source
Is there a role for oral triple therapy in patients with acute coronary syndromes without atrial fibrillation? [PDF]
, 2018 © 2018 Bentham Science PublishersBACKGROUND: Acute coronary syndrome (ACS) patients, despite treatment with dual antiplatelet therapy (DAPT), have up to 10% risk of recurrent major adverse cardiac events (MACE) in the short term.
Akhtar, Zaki +3 more
core +2 more sources
Thrombolysis in a stroke patient on dabigatran anticoagulation: case report and synopsis of published cases [PDF]
, 2013 We present the case of an aphasic 77-year-old stroke patient with left distal M1 occlusion who received rt-PA for thrombolysis while on oral anticoagulant treatment with dabigatran (150 mg b.i.d.).
Abruscato, Mario Giovanni Rosario +3 more
core +2 more sources
A three-year prospective study of the presentation and clinical outcomes of major bleeding episodes associated with oral anticoagulant use in the UK (ORANGE study). [PDF]
, 2018 The outcomes of patients developing major bleeding while on oral anticoagulants remain largely unquantified. The objectives of this study were to: (i) describe the burden of major hemorrhage associated with all available oral anticoagulants in terms of ...
Alikhan, R +10 more
core +3 more sources
Current clinician perspective on non-vitamin K antagonist oral anticoagulant use in challenging clinical cases. [PDF]
, 2020 OBJECTIVE: The evolution of non-vitamin K antagonist anticoagulants (NOACs) has changed the horizon of stroke prevention in atrial fibrillation (SPAF).
Acar, RD +12 more
core +1 more source
Relative effects of different non-vitamin K antagonist oral anticoagulants on global thrombotic status in atrial fibrillation [PDF]
, 2016 This is an Accepted Manuscript of an article published by Taylor & Francis GroupNon-vitamin K antagonist oral anticoagulants (NOACs) reduce the risk of thromboembolism in patients with atrial fibrillation (AF).
Artman, Benjamin +8 more
core +2 more sources
Provider Specialty, Anticoagulation Prescription Patterns, and Stroke Risk in Atrial Fibrillation
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018 BackgroundDifferences in anticoagulation rates and direct oral anticoagulant use by provider specialty may identify an area of practice improvement to reduce future stroke events in patients with atrial fibrillation (AF).
Wesley T. O'Neal +9 more
doaj +1 more source
Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice. [PDF]
, 2018 © 2018 Vimalesvaran et al. This work is published and licensed by Dove Medical Press Limited.Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and it leads to significant morbidity and mortality, predominantly from ischemic stroke.
Dockrill, Seth J +2 more
core +3 more sources
Stroke Research and Treatment, 2017 Background and Purpose. Anticoagulant therapy is broadly used to prevent thromboembolic events. Intracranial hemorrhages are serious complications of anticoagulation, especially with warfarin.
Kyle M. Ware +10 more
doaj +1 more source
, 2015 The bottom line Clarify the warfarin dose that the patient is taking, and check for co-existing problems (such as liver disease or cancer), dietary changes, and intake of alcohol and other drugs that may increase risk of bleeding or affect ...
Chevassut, Timothy J +2 more
core +1 more source